Login / Signup

Cotreatment of congenital measles with vitamin a and intravenous immunoglobulin.

Yasemin OzsurekciAteş KaraCihangul BayhanEda Karadag OncelSahin TakciSultan YolbakanAyse KorkmazGulay Korukluoglu
Published in: Case reports in infectious diseases (2014)
Although the measles vaccine has been part of routine national childhood vaccination programs throughout Europe, measles remains a public health concern. High numbers of cases and outbreaks have occurred throughout the European continent since 2011, and an increasing number of cases have been reported in Turkey since 2012. During a recent measles outbreak in Turkey, 2 pregnant women contracted measles prior to delivering preterm infants at Hacettepe University Hospital. Measles virus genomic RNA and IgM antibodies against measles were detected in the cord blood of infants and mothers in both cases. The infants were treated with intravenous immunoglobulin (IVIG) and vitamin A. Transient thrombocytopenia was present in 1 infant and treated with an additional dose of IVIG and vitamin A. The infants were discharged, without complications, within 10 days of birth. The successful treatment of these cases suggests that infants who have been exposed to, or infected with, measles may benefit from cotreatment of vitamin A and IVIG.
Keyphrases
  • public health
  • pregnant women
  • preterm infants
  • cord blood
  • high dose
  • gene expression
  • low dose
  • young adults
  • gestational age
  • copy number
  • cerebral ischemia